PDS Biotechnology
PDSB
17 hedge funds and large institutions have $2.12M invested in PDS Biotechnology in 2019 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 17 closing their positions.
22.83% less ownership
Funds ownership: 28.2% → 5.37% (-23%)
33% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 6
45% less funds holding
Funds holding: 31 → 17 (-14)
82% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 17
88% less capital inflows, than outflows
Capital inflows: $136K | Capital outflows: $1.1M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$101K |
| 2 |
D.E. Shaw & Co
New York
|
+$14.6K |
| 3 |
Panagora Asset Management
Boston,
Massachusetts
|
+$14.6K |
| 4 |
Tower Research Capital (TRC)
New York
|
+$3.09K |
| 5 |
FNY Investment Advisers
New York
|
+$1.67K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
New Leaf Venture Partners
New York
|
-$753K |
| 2 |
Anson Funds Management
Dallas,
Texas
|
-$78K |
| 3 |
Two Sigma Investments
New York
|
-$76K |
| 4 |
Raymond James Financial Services Advisors
St. Petersburg,
Florida
|
-$51K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$39.7K |
PDSB Hedge Fund Activity: Q1 2019 in Review
17 of the 4,634 institutional investors tracked by Wall St. Rank reported a position in PDS Biotechnology (PDSB) for Q1 2019, worth a combined $2.12M — down 25% from $2.83M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of PDSB and 3 opened new positions — a net loss of 14 holders — while 6 trimmed existing stakes and 4 added.
The largest buyer was Renaissance Technologies, adding an estimated $101K. The largest seller was New Leaf Venture Partners, exiting entirely with an estimated $753K sold.
- 17 institutional investors held PDS Biotechnology (PDSB) as of Q1 2019, down from 31 in Q4 2018.
- Funds reported $2.12M of PDS Biotechnology stock for Q1 2019, down 25% quarter-over-quarter.
- 3 funds opened new PDS Biotechnology positions in Q1 2019 and 17 closed out, a net change of -14 holders.
- The largest PDS Biotechnology buyer in Q1 2019 was Renaissance Technologies, an estimated $101K added.
- The largest PDS Biotechnology seller in Q1 2019 was New Leaf Venture Partners, an estimated $753K sold.
Based on aggregated 13F filings for Q1 2019.